Loading stock data…
DarioHealth Corp. (DRIO)
$6.80-0.23 (-3.27%)
Market ClosedLast close Jun 29
DarioHealth Corp.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
DarioHealth Corp. in the Healthcare sector is trading at $6.80 with a market capitalization of $56M. Wall Street consensus targets $18.50 (4 analysts), implying a +172.1% move over the next 12 months. The stock is currently near its 52-week low of $5.84, remaining 34.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +172.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.58M↑ | $5.23M↑ | $5.01M↓ | $5.37M↓ | $6.75M |
| Gross Profit | $3.20M↑ | $2.80M↓ | $3.02M↑ | $2.96M↓ | $3.88M |
| Operating Income | -$7.31M↑ | -$8.56M↑ | -$9.48M↓ | -$9.20M↑ | -$9.41M |
| Net Income | -$8.25M↑ | -$9.03M↑ | -$10.47M↑ | -$12.99M↓ | -$9.23M |
Peer Comparison
JNJUNHPFE
Fundamentals
DarioHealth Corp. operates as a digital health company in the United States and internationally. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$55.94M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-65.30%
Volume
Today's trading volume
12,854
Recent News
DarioHealth (DRIO) Upgraded to Buy: Here's Why
DarioHealth (DRIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
DarioHealth Corp (DRIO) Q1 2026 Earnings Call Highlights: Navigating Growth and Strategic ...
DarioHealth Corp (DRIO) showcases revenue growth and strategic partnerships amid operational challenges and future opportunities.
DarioHealth Q1 Earnings Call Highlights
DarioHealth (NASDAQ:DRIO) reported sequential revenue growth for the second straight quarter while outlining plans to expand its digital health platform further into care delivery, management said on the company’s first-quarter 2026 earnings call Wednesday. Chief Executive Officer Erez Raphael said
DarioHealth Reports Q1 2026 Results: Full Earnings Call Transcript
DarioHealth (NASDAQ:DRIO) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more. The full earnings call is available at https://viavid.webcasts.com/starthere.jsp?ei=1756269&tp_key=7306dc53e7 Summary DarioHealth reported a revenue of $5.6 million for Q1 2026, marking the second consecutive quarter of sequ
DarioHealth Corp. (DRIO) Reports Q1 Loss, Beats Revenue Estimates
DarioHealth (DRIO) delivered earnings and revenue surprises of -14.09% and +0.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?